Rick Klaus­ner's Lyell part­ners, helps fund Eu­reka's work on cell ther­a­pies; Blue­print bounces high­er on PhII

→ Lyell chief Rick Klaus­ner con­tin­ues to build up his net­work of com­pa­nies beaver­ing away at new cell ther­a­pies. The Glax­o­SmithK­line part­ner led a $45 mil­lion E round for Eu­re­ka Ther­a­peu­tics, which is work­ing with en­gi­neered T cells on sol­id tu­mors. Klaus­ner, a for­mer di­rec­tor of the Na­tion­al Can­cer In­sti­tute, al­so found­ed Juno and Grail. The fund­ing comes with a strate­gic re­search col­lab­o­ra­tion be­tween Eu­re­ka and Lyell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER